<SEC-DOCUMENT>0001193125-13-263459.txt : 20130619
<SEC-HEADER>0001193125-13-263459.hdr.sgml : 20130619
<ACCEPTANCE-DATETIME>20130619080425
ACCESSION NUMBER:		0001193125-13-263459
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130619
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130619
DATE AS OF CHANGE:		20130619

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21392
		FILM NUMBER:		13920848

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d556369d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): June&nbsp;19, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Amarin Corporation plc </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>England and Wales</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-21392</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer<BR>Identification No.)</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2 Pembroke House, Upper Pembroke Street 28-32, Dublin 2, Ireland</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Former name or former address, if changed since last report </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01.&nbsp;Other Events. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;19, 2013, Amarin Corporation plc (&#147;Amarin&#148;) issued a press release titled &#147;Amarin Informed by FDA of
October&nbsp;16</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Advisory Committee Date in Connection
with Supplemental New Drug Application (sNDA) for
Vascepa</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(R)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> in the Treatment of Patients with High
Triglycerides (<U>&gt;</U>200 mg/dL and &lt;500 mg/dL) with Mixed Dyslipidemia.&#148; A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)&nbsp;Exhibits </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:23pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated June&nbsp;19, 2013</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: June&nbsp;19, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amarin Corporation plc</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John Thero</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Thero</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit&nbsp;Index </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:23pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated June&nbsp;19, 2013</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d556369dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g556369amarin-ex99_11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amarin Informed by FDA of October&nbsp;16<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Advisory Committee Date in Connection with </FONT></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Supplemental New Drug Application (sNDA) for Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(R)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> in the Treatment of Patients with </FONT></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>High Triglycerides (<U>&gt;</U>200 mg/dL and &lt;500 mg/dL) with Mixed Dyslipidemia </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>-Submission for Indication Studied in the ANCHOR Phase 3 Clinical Trial Under Special Protocol Assessment Agreement with FDA- </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">BEDMINSTER, N.J., and DUBLIN, Ireland, June&nbsp;19, 2013 &#151; Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company
focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it was informed yesterday by the U.S. Food and Drug Administration (FDA) that the FDA will convene an advisory committee on
October&nbsp;16, 2013 in connection with the FDA&#146;s review of the Supplemental New Drug Application (sNDA) seeking approval for the use of Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (icosapent ethyl) capsules as an adjunct to diet in the treatment of adult patients with high triglycerides (TG <U>&gt;</U>200 mg/dL and &lt;500 mg/dL) with mixed
dyslipidemia. The FDA has previously assigned a Prescription Drug User Fee Act (PDUFA) date of December&nbsp;20, 2013 for completion of its review of the sNDA. The FDA will consider the recommendation of the advisory committee, but the final
decision regarding the approval of the sNDA will be made by the FDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;ANCHOR clinical trial results demonstrated the important role
EPA-only omega-3 can play in helping adult patients with high triglycerides and mixed dyslipidemia,&#148; said Christie M. Ballantyne, M.D., Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas, and
principal investigator of the ANCHOR trial.&nbsp;&#147;In the ANCHOR trial, Vascepa lowered high triglyceride levels and showed robust reductions in a broad range of other lipid parameters on top of optimized statin therapy compared to placebo.
Importantly, these beneficial effects were seen with a safety and tolerability profile comparable to placebo.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vascepa was approved in
2012 as an adjunct to diet to reduce triglyceride levels in adult patients with severe (<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia, based on the results of Amarin&#146;s MARINE clinical trial. The safety data from
both the MARINE and ANCHOR clinical trials were reviewed by the FDA as part of the approval of Vascepa in the MARINE indication and are reflected in the approved product labeling for Vascepa. As is customary practice at FDA, yesterday&#146;s
notification from the FDA is the only communication confirming the need for such a meeting. The FDA advisory committee topics and questions to the committee are anticipated to be made public by the FDA on its website in the week preceding the
meeting, consistent with FDA procedure. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;For key first-in-class indications, an FDA advisory committee meeting is expected, and this public
forum will be an important opportunity to discuss the ANCHOR data, which demonstrated Vascepa&#146;s unique potential as an adjunct to diet in the treatment of adult patients with high triglycerides (TG 200-499 mg/dL) and mixed dyslipidemia,&#148;
said Eliot A. Brinton, MD, FAHA, FNLA, Director of Atherometabolic Research, Utah Foundation for Biomedical Research, and President, American Board of Clinical Lipidology.&nbsp;&#147;Currently, many of these patients are receiving another
prescription omega-3 which is not indicated for this disorder.&nbsp;Having instead an omega-3 product which lowers LDL-cholesterol in addition to triglycerides, has tolerability comparable to placebo, and is FDA-approved for use on top of statin
therapy would be a welcome addition to the physician&#146;s armamentarium for comprehensive lipid management.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;With the support of
the Amarin team, including our outside consultants, such as Christie and Eliot, we look forward to the advisory panel and working with the FDA to obtain regulatory approval of Vascepa for ANCHOR this year,&#148; said Joseph Zakrzewski, Chairman and
Chief Executive Officer of Amarin. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, Amarin only markets Vascepa for the MARINE indication, for which it was approved in 2012, and
which includes approximately 4&nbsp;million patients in the United States. The proposed ANCHOR indication would expand the Vascepa patient population to include adult patients on statin therapy with triglyceride levels ranging from 200 to 499 mg/dL
(and mixed dyslipidemia).&nbsp;Amarin estimates that one in five, or nearly 40&nbsp;million, U.S. adults have triglyceride levels in this range. Amarin began selling Vascepa on January&nbsp;28, 2013. Amarin believes that many of the same clinicians
who have prescribed Vascepa for its currently approved indication will prescribe Vascepa for the much broader indication, based on the ANCHOR study now under formal FDA review, if approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Amarin </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation plc is a biopharmaceutical company
focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin&#146;s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(R)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (icosapent ethyl),
Amarin&#146;s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&nbsp;(icosapent ethyl) capsules </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Vascepa<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP>
</FONT>&nbsp;(icosapent ethyl) capsules, known in scientific literature as AMR101, is a highly pure-EPA&nbsp;omega-3 prescription product in a 1 gram capsule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Indications and Usage </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vascepa (icosapent ethyl) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (<FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>500 mg/dL) hypertriglyceridemia. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been
determined. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Important Safety Information for Vascepa </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vascepa is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of its components and should be used
with caution in patients with known hypersensitivity to fish and/or shellfish. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most common reported adverse reaction (incidence &gt; 2% and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0% for placebo).
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND AT&nbsp;WWW.VASCEPA.COM. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press
release contains forward-looking statements, including statements about whether the FDA will hold an advisory committee meeting in connection with its review of Amarin&#146;s pending Supplemental New Drug Application, the expected timing and outcome
of the FDA&#146;s review of such regulatory submission, including the timing and outcome of the proposed advisory committee meeting, the efficacy and safety of&nbsp;Amarin&#146;s&nbsp;product candidates, market opportunities for Vascepa, the
potential for clinicians to prescribe Vascepa to expanded patient populations in the future, and the clinical importance of Vascepa. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties.
Among the factors that could cause actual results to differ materially from those described or projected herein include the following: uncertainties associated generally with administrative decisions and the bases for such decisions, research and
development, clinical trials and related regulatory reviews and approvals, and uncertainties associated with the commercial uptake and market expansion of new pharmaceutical products. A further list and description of these risks, uncertainties and
other risks associated with an investment in Amarin can be found in Amarin&#146;s filings with the U.S. Securities and Exchange Commission, including its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future
events or circumstances or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vascepa has been approved for use by the FDA as an adjunct to diet to lower triglyceride levels in
adult patients with severe (<U>&gt;</U>500 mg/dL) hypertriglyceridemia. Vascepa is under various stages of development for potential use in other indications that have not been approved by the FDA. Nothing in this press release should be construed
as marketing the use of Vascepa in any indication that has not been approved by the FDA. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amarin contact information: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Joseph Bruno </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investor Relations and Corporate Communications </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In U.S.: +1
(908)&nbsp;719-1315 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">investor.relations@amarincorp.com </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g556369amarin-ex99_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g556369amarin-ex99_11.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`0P$]`P$1``(1`0,1`?_$`.$```("`04!`0``````
M```````*"0L(`0,$!@<"!0$``@(#`0$```````````````<%!@$$"`(#$```
M!@$"!`(%!0D*"0@+```!`@,$!08'``@1$A,)(0HQD2)2%$%A,A4647&!P4*"
M%[<Y\+%R(T,V-SAX&J'1\224976VEV(S@S0U5=<89+5F=M:G*$A8&3H1``$"
M!`,$!`D&"@@$!P````$"`P`1!`4A,09!46$2<8$R!_"1H;'!(K(3%-%"4G(C
M-6*"PC-S-'05%C;A\9*BTD.S)%.#)3>3T^-$5"87_]H`#`,!``(1`Q$`/P!_
M10XDX<`X\>/^#A_CT01M=<?=#UCH@@ZX^Z'K'1!!UQ]T/6.B"-06$?R0]?R_
M<U@D#M=G?L@\\0*]RWO^;8^WCG7$&WI9JAE>_3U[K"&?4J],I%9[?\52CM)"
M4LD^LV1>`_O9&KDKQK`\4E19)'57.B!VX+7G3VA;G?J!ZX_FJ9#:BV2/SBQD
MD?@GZ7BVQ6KKJ2EME2W2^JMPN27(]E/5FKAZ2)SM14Y&ST5&3L(^9RL+-1S*
M7AY1@X(Y8R<7)-DGL?(,G"0F37:/6BQ%$SE$2F(8!#P'5)4A:'%-K!"DX&>P
MC`CI!BQI4%I"TD%)].(\D<_KC[H>L=>8]0=<?=#UCH@@ZX^Z'K'1!!UQ]T/6
M.B"#KC[H>L=$$'7'W0]8Z((.N/NAZQT00=<?=#UCH@@ZX^Z'K'1!!UQ]T/6.
MB"#KC[H>L=$$'7'W0]8Z((.N/NAZQT00=<?=#UCH@@ZX^Z'K'1!!UQ]T/6.B
M"#KC[H>L=$$'7'W0]8Z((.N/NAZQT00=<?=#UCH@@ZX^Z'K'1!!UQ]T/6.B"
M#KC[H>L=$$'7'W0]8Z((.N/NAZQT00=<?=#UCH@@ZX^Z'K'1!!UQ]T/6.B"#
MKC[H>L=$$'7'W0]8Z((.N/NAZQT00=<?=#UCH@CD<?#C\W'_``:((V%_R/SO
MQ:((X^B"#1!!H@B'GON;@]T.UOMN9DS7M1M%2I5UK+VKQULM\_TOM)6J#:YA
M"K2LOC$KQ8D6?(3>4F&8-/B$G`IH&6413%PFD(6S1%!;+EJ)FAN25+95,A([
M)4/6]?`^K*<\L<(@=1U-91VMQ^D(2N8!.V1PPQP,R.@>.*H&:FIBR2\M8+'*
MR4_/3\B]EYZ<FWSJ5EYN6DEU'4C)RTD]56>2$@^<JF4665.910YA$PB(ZZH;
M9:90EMM(2V@``#(`92&Z$8MQQUPN.$EPG/;%C_Y73N&AN;V@/=IN09KXK,>T
M-M'P\$9ZY,K)6K`LJJHE1Y0!5$57*M(?%4@G(\1!-L1B)O%77.O>78/W9=Q<
MZ<?[*JQ(W.;>@J[73.'#H^["NH?AG"/?LX=(/^'+@"(:%TM8N$&B"#1!!H@@
MT00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00
M:((-$$&B"#1!!H@@T00:((-$$&B".=^1^;^+1!&RO^1^=^+1!''T00:((-$$
M*(=\*]V#N+=P?9SV3L2R\BE5CVV$S?N]FH)3G^HZXQ8.)IG%O3$$R*3BK4!)
MY)E*M[`R4O&!P$Y0#35T6PWI^Q5>LJM,W.4ML3`D3ETXKDF8V`[(I.H7%7.X
M,V-DGD*@5RF9'<9923-4C@9B$WNZ'L8L7;NWJ9?VV2A9!W48F6&U8@LL@415
MMF(+4JN^I4JHX*`(NI.-:E/&2)B>R$DQ7#@`<`TXM+WU.H+0U7I`]^1)8W+'
M:3T;0=H(A<WRUKM->NF.*)S2=XV>/SS`RC@]LO>]9^WIO1PYN8@U';BN5^:^
MS>5J\U4,4+7B*U*(1UYACI<#D7=-&0$D6(&`>608H&^36-369F_69ZW.GE>Q
M4@RGZP[)GTY\)C;&+'<E6NX-U*>SD1O&T=8PZ9'9%OY3[=6<@5*KWRES#.Q4
M^Z5Z'M=6GXY4%H^:KU@CV\I#RC-4.'.W?1[I-0@^`\#>(:Y->9=IWET[Z2EY
M!*2#L(,B.K*'TVM#J$NMF;:D@@[YQV+7SCW'#D7[2*CW\K(+`W81;)W(OG`E
M.<$&3%!1RZ6$B13J'Z2"1C<"@)AX<``1UE*%.*#:.VI0`ZS&%*2D%:S)(!)B
M%_\`O$W9O!0Z8[SJ_P!1,QBG3_1KF3G*)#"0>)1Q]S<`,'#[@ZMPT'JDJPIC
MCEZR)2X8Q`JU+:$=IPR!^@J7492CZ_O$G9Q#_P"\R`_X:YD_\/M>AH#5A5R"
ME/,<O63C_>CR-4V7_C8_47\D2>[=MQN%-V.(JOG?;U?8O)>*+D,H2O6R*0D6
M2+M>$E7D)+M'$=,,XZ7C7L?*,%4E47*"2I1+QY>42B-9KZ"MM=4JCKVU-U"<
MP983Z,)<8F:6KIZUD/TR@IO*8F,1GG'MNM2-B#1!&!F[KN=;%]B-GJ-+W69^
M@L4VN]03VSUB!=5ZY621?U]@_"+7EED:C7IWZO9GD.9%(SGI=<Z:@)\W3/PG
M+3IN\WQMQVUL+=;;4$D@I&)W3B-KKM06Y015K*5D9`3Z,IYR/BC$?^\2=G'_
M`/,V`_X:YC_\/]2O\`ZK&)I5`?63\L1_\46;_C?W%?)&3^TONL[!-\^09G%F
MU?<#%Y7OE?JKN[2\"PJ-^@CLZPQDXV'=29GUIJT)'*E2D99NGTR*F5$5`$"B
M`"(1=UTS>[*RE^Y,^[:4J4PI)QZB3C$A27:AKG2S3KYG`)R*5##K`B0S4%$E
M&H`(CP`./S:P3(;O#9!LC$S`V^/:WN;RSG[".#LLP.0,C;9IV(KV6X>&^(.U
MB7TR@L9):'ECIA&V:/8R+1Q'/'#%19)I)-56Z@E.`<92OLURMM,S5UK2VJ>H
M22VHC/=,;"09R.PSC2IKA25CSE.PL%YKM`9=1W;(RS$-18GG&[QV1IK,$82;
MJ.X]LDV1VBG4[=9N!J^%;!?X.2LE0:V>*M;EO-0T0_1C)%VE(P4!+1[<6KU<
MA!36434'F`0`0\=2]ML-VN[:W;8RIY#9DJ1`E/I/FC2JKC1T:@BI5RJ5E@3/
MQ`GQQC&OW[NSZW1%8V^O%*A0X>RVBLA.E3<0$0Y$F]-44-Q^8.&I%.B=6*.%
M"]+H'RQIJU#9DX>_$QP5_ACSN8\QMV;883%4WAQKX2CPXQ6*\SOR&\>'L*I8
M_P"B/#T_2]`:VT]WVK%)'^VES9$J3GXXU_XHLL^4.+)^HH^9,;M;\QAV;K.Z
M(U:[QX6,.<W("D_C7,$,T+Q$``ZCUY0RM4DQX^DQPX?+PUY=T#JMI,_A9X;%
M)5YE1[3J6T'!;A0K\)"QZ(DGP)O#VJ;I69GNW7</A[,P))==RQH-\@)V<8I`
M4#">2KK=[]?1H`4?'XALGP^75=K;3=+:>6XL.LJ_"00#T$X'JB3IJ^CK1.D=
M;7T'T1DAP\=1Y)E,`X@RW=>V-R1.R1\\8=;P-_NT?83#4>P[L\O,L1PV1Y:8
M@Z8^?5RX6%.9E(!BVD99L!:E`3JC,6K-XF?F7!(IP-P*(B`@$K:[+<KRMQNV
MH#BFD@JQ`E/I(PC1J[A2T"0JI40#AD3CU8^B,%P\Q+V;S`!B[S:^)3!Q*8,:
MYD$H@/W!_1]XZG?X!U5_\8DG'!2,CUQ&*U/9DF1>D?JJ^2`?,2]F\H"8V\ZO
ME*`<1,.-<R```'W1_1]P#0=`ZJ`F:8C\9'RP)U/9E&0=F?JJ^2-LWF+.S43E
MY]Z-=*!N'()L;YC*!P'T"01Q\`&#[VL?P#JPB9I3RG;S(]*C'T&I+09\KA,L
MY(7ATX1N_P!XD[.(^(;S:_P^;&N8^'ZO]9_@'5>RD5_:1\L?(ZGLP_SO[BOD
MCV3`'>F[8NY_+%6P=A/==4;7E&[JNFU1J[ZMWRI'L+]HU4>&BHR4M]6@H=Q,
M.&Z1Q;M`<?$.C%Y$2'/P*.I<-'ZDME*JMJZ58I42YE`I/*#MP)RV[HV::_6J
MK=%.R[-U66!&.[$9Q*/JL^6)B/DYR)D.HH8")I$.HH8?05-,HG.8>'$>!2E$
M=`!)D,X"0!,Y"(?7_?Z[/<:N[:NM\>.?BV+E=FZ:(UG)R[A)PU7.V<)BDE1S
M&-TER"4PAQ#P^YJUM:'U8\9(HU[-HS(F-N.$0Z[_`&IM)*W,C+(_)CU&/P'_
M`)AWLWQZ767WKU(Q!Y^!6U`R\Z5'D()Q$$D*`=0>!2_(`\1\-?5.@=6$!1I5
M!!WJ2/.J/B-26@X)=*CP2HR\0B7S](E._1O^EGZY)^C_`.Q'Z1/M#\*]Z?V.
M^H?M+]<_!?#?6/)]2?Q_2Z/7X>SR<WLZJOP[OQ'PLOM^?DE^%.4MV<3/OF_<
M^_G]ER\T^$IS\4=P7#CR^(!]+TB`?<^Z(:^,B<@3'UF!F?-Z8XPF(4>`J)`/
MW!4(`^H1XZ]!"R)R5XI^B#F1O'AT1Q#R,:03%/)1Y#$$0.!GK4HD$OT@,!E0
M$HA\O'T:S[MXF02K^S_5'@K;![0'ATQCMNDW4XJVG[=\Q;C;_8(A6KX@HDY<
M7D>TEF!W\X]CVQ@A*W&D(LH925LLTHW8MB@4>*RY?#6];+567.O:M[22'75@
M`D$``[3/##';&K5US%)3+J%D$($\",3L$IYDPNEY:#`=ORD?=-W;-P1T)'-F
M\S(EJBZ.J]5(JYA<;L+&=]:G\8"Y15:Q<Y:VZ$4S`!*)(ZO)%#^+4`!8'>)6
MHI_AM+V\*%%2MIYL,U2D!A@9)]8G:I6\15]*L%U3MYJB/B'E$#@)S4=AQ.`&
MR6XQZ5YH#MX?^:C9ZUW28ZARO\T[06LM8I)*/3Z\E:L$R)DG&08<2(<ZKE6F
M*MTYYJ'`>1%!Z4OBMK7[M;]^Z[O^[:F8HJHR&SE<'9()&'-D>,MT>]7VU%PH
M34M8U#..$NR<YX_-\@)E%:^!N8`$!`2B`<!#T"`^@?O"&NC]G"$Z?5)GG%AC
MY4GN(?IEV^6K8;D>;^(R+ML:GL^(E7S@HN[!@J<DQ(O"-^H;J+JXRL[X&X%#
MCR1TBT(4.5$W#GSO0T]\%<$WNF!^&?)"^#F\\%C+>0=\-O1=V%52F@>/VS79
MQQ(.?B./09#*&YM*J+S&ABE,4Q3%*8I@$IBF`#%,4P"!BF*("4Q3`/`0'P$-
M9!(R@X;(66\SWMRP8IVN\AY7:8=QZRR1CG(V)GE5O,+4(.'M$(A8;Q&5VP-R
M3,6R:/EHN5BI-1)=LJ<Z!S"0XEYR$,5B]V]QKAJ=JG4ZLTRT+YDE1(/*A1&!
MPF")B*AJ^CIOW,MU#:`ZE29$``CF4`?'%=KFC!M\P1*4*-O+$K=/)F(<:YOI
M,B@18&,[0LHUU">@I%FHL0@J':+"X8.@#B!'C-4G$0`-=#4=:Q7)<]R9^Z=4
MA6\*2<?Z.$*.JI7:;E+@DE:`H=!$-O>4>WX#5LBY8[?-ZF03A,DHOLTX,3>.
M.5-O>H!B@VR74H\AQY>I8ZLU;RR:9>'`T2Y,`<5!'2G[U[#[UEJ^LCUD?9N2
M'S3BE1Z#,'I$7_0ET(6NV.G`B:9[",Y=(]GC#ZW[OW<-(N<X9GFC\N=G8:KP
M<U9[')-(:O5R(DI^>F'ZH(,8J%AF2TC*R3U<WLHM&+%LHJH<?`I"B.O:4*<6
M&FAS.J*4@<591Y6H-I*UX(2)D\(J=.[#EW*^^;+-W[E5B2<1^"<P9TNVW?;7
M&ORKD<GQY@J`A5V[F.3$A6Q6`M[$W<O3%\3R\@Y#^3'74NDZ2DLM(WI]H@UC
M;*'G3M2XLJS/49<)0E-0N/W"H5<G,&%+*4]">7+`;")\>:([MMU?AK;N,V^5
M2R1S>7KMHSGB&N6"(=E,9I*P<YD*NQDM&.BD,0YFS]@Z424`!`1(<0XZL%W=
M<8M-2\T2EU##B@1F"$D@B(6VH0Y7-(<`*"H3$7.U*Q3B_&;5O'XYQQ0Z"Q8L
M$HEFUIE0K]81;1;<$R-XY$D+'L@(S1*B3E3^@'*'AX!KC]ZKJJA1-2XXLDS]
M91..TXF.@FV&6,&4)3A+``82RPCO0:U^.P1]85-\TKOVW1;1L*X5Q+M^OM9Q
MQ7]S1<A5[(EG@Y%VWSFC$5AM"'<Q=2,4"(UFH3K2<%N^EVQOK$%0!ND=`JAC
MF9W=E8;;=JYVHN#:W%T_*I(_R\9D%6\B67@*5K*Z5E!2H;I%!`<YI_2E,##A
M(PEAVL-^]I[<N]'&&XR-5DGM(!Z:G9LJ[18YC7'$UG=-TK2V,B8PINIB$.1.
M6CS'XB#]D0./`Y^+FU18F;_:':!SE#\N9L@8)6.SCN.1X&%Y8KJ[;+BFHG-$
MQS<0<^N67&6P1;OU"WUG(%2J][I<VQLE/NE>A[75;#%J@XCIRNV"/;RL-+,5
MPX`JTD(]VFJ0WAQ*;7)SK3C#JF7DJ2^A1"@<P09$>,0]6G$O-AU!!;4)@C:#
MB([%KQ'N.JV6@T2\E11NU)J-Q1135012M5:A;"1)!SP*Y12++LG@)I+E#@<H
M<"F^4!U]6GWV"?<K6C(^J2,9YX1\ULLNF3J$JP.8!\\4\_<DJ57H/<(WM4FD
M0$75:?5=T>:H2LUJ#:),(6!AF-[F4F,5$L$`*@RCF2(`1%$@`FD0`*4`*``'
M7&FW77]/T;SZBMY5,V2HF9)*1,DPA+XVANZOH;`2@.+``R$E*'F$3Y^44I52
MNN\[=(WN%8KMJ8L=KS%5LPLL%%SS-%RXRI5$A=(H2K5VD@N")#$$Q2@82'$!
M'AX:H/>P^[3VRE2PI2%&H(FDE.'+.6&R>,6O0C+;E2Z'$I4`@RF`=J-_3#E^
MZGM']O/>#3IBK97VP8MC9619.$8[(V.*I"XYR76GZJ1B-Y>(ME38QCQ=TR5,
M!RH/@=LE1+RK(J$$2BH+7JJ_VE]+E+4.R!]9"U%2%<)$D8\)1?JRR6NN06WF
MD)41+F2`)<9CTS$5>F]3;5E3MD;Y<K8&C+Y8XJZX2M[%Y0<JU-_(4ZQRU3FH
M]A::);F3Z'=-WD7(/H*2;BY(BJ*:;M-4A1$I0UTQ9KE1ZELK-:XVDL.H(4DB
M?K3DH$;@1A":N%/4V6X*80I0+:L);=Q'41Q$\YP[/Y<KO993WP/+'LZW722-
MHSKCZC*7;'>7NBV8RF4Z3"/6,5/1-S8LT4&:UWK(2+5;ZP1(F$FT.<ZQ`72.
MHNF.\+1C%E(NUL'+1.+(6WL0K9R_@D^(X##)BZ3U"Y<4FAJS-](FDXS(`Q!.
MT[=^<\IEJ6PU.JV]JFRME8KMH9H',JBTL<)&3C5%10O3.HDWDVKI),YR>`B`
M`(AX#I9-O.LF;2E))SD2-G"+HM"'?5<`4.(G%4'WZ<<4+$_=HW@4O&=1@*+4
M&UGI$PSK%8C6T/`L)"SXNI-BGEHZ*9D291R4C-R;AR9)$A$BJ+&Y2E`>&NI]
M#/OU&F*5U]:EN%LXJ,S@H@8GA"-U0VVU>GD-)"4!6``D,@<NDQD%Y:+"&(L\
M]T6J5O,^/*MDVM57#>4,A0U;N<4WG:\E<*ZM5FL',O(-\56,E58LDNN=%-TD
MLB182J<G.0ABQW>36U5)II1I7%MK4\@$I,C(\P(F,<8WM%TS%3=N5]"5I""9
M$3'BBRYF=N^W^R,/JBQ8*PU/172^'^K9G%](DV`("7I]$&;R#60!+D'EY>7A
MPUS@W<;@DA:'W@Y/,+4#YX;RJ.D7]FIMLH(/S1++HBKLW3]NNXYF[FW<LP%L
MPQU%%:;;I_+.5*[AV!,LBZ=X^J=DK#29JV.V!^L#R5BR6OXAC%@8HK-T#-V_
M%3I)&Z9M>H6*'3=NK+LXH&I0VV5G'UE))YE'8#(B9RSA-U]H74W>JIZ!*1R<
MY"1N2HY#@)"0QB&UB_F*[,-)*,>RD!8("30>L)!BN[B)N"FXAV5=L[:.43-W
M\5+1<@W`Q#E$BR"R?$.!BZN'*T\WZP2IM2>D$'R$$16^9QAR8FEQ)\1ZHL?^
MP)WU(_?)68C:?NFL+",W?4R%*E5+<_5;,&NXZL1#8>M)-R<J#='*<(Q1YY5F
MGP^L42F?(%\'*:7.VO-$+LCRKG;4E5K4?62/\I1\Z-V[([(;^E]1IN30I*LR
MK4C`GYX&_COWYC&<-#:6D7&(I>ZAV_-J^Z'9/N*B;UB*AQUFJ&*<C9)H.1*[
M48&'NU*O%1K$K9XZ9B9V-9,WYT7SV.*E(-5%#-WS=0Y%2F$2B6T:;OMSMUXI
MU-/.*;6ZA*DE1Y2DF4B.$\-QB$O-LHZNW/!QM'.E"E`R$P0"9S\AB%WRGVS?
M;Z^V3VS=A:,<5&ZYFR%F.YTE.SVZN0]A=5"G4-K!M6$%4SRK1V,.G*2$@X=O
M54>FJY.9,AQ$B1`U;N\^]5RKTFW-K6W2LLI/*"1-2L23+=D/Z8A-(6RD9HE/
MJ2E;JG)`D#`!(/EGZ(<$^&;_``GP?PZ'PGP_PWPO13^&^'Z72^'Z'+TNATO9
MY.'+R^'#AI5<RN;FF>:<Y[9Q=9"4MD0S]WS'&+KTRP,YR+VX=R'<&5BWN0$(
MAKMYODG27&+$WK:J*/G5J%AD?'Y9%O;#,T4VG.+KI'8J<.GS#SVK3#U0R7OA
MZ]BBGRS]XD'G[64P>SMZ1$)>:=A_W8?IW'Y!4N4J$NS@>6>)S$\,#MS@]?;>
MMJ8&*L\\M+W)W*A_8!0N9+*_5X%#P`XH[AW"A"@`^'-P#[FK>FKN8[.H*(#Z
MJ/\`!%?5;[=A.WO^-WT".IO-M>SP!6=K>6C[G(%.<3G(ADZV..'.;@($22SF
MLL8O$?N#X>G6VBXW:7*+];STI1/S1X-MMAQ_=]1XW?\`#$-6_P"QK@C+F:<)
M;+MEW:@W2;5-R+^Q?:C(]!O]QG;=F"XT=U"'DHF)JE0FKY9J_%-"P[5_+*/I
M`S8`%NAX@CSB-PL-174U(]=KK<Z5^A"2$%(2$`@CF4I0QP,DR$5^Z4U&[4MV
MZ@I'&WRJ:A-941($"2A/+'*)TJ=M3VJUJ)A8<_EFM]ZA8IHT8K2;C,<(]D),
M6B1"&D90&FX&&9NG\@HGU'`)H(HBH<W*4"\`"B/W2YNNE9U#2S)/S!(">0FD
MX#8-T69-MMZ$@"VN'#>N9\@QB83ML;4]JS2X9`R-7NU#E;8C=(:KFI*,EG&R
ML+2ED.HY`1>(VN#@V$5E[)$6JT2;Q**<B1ZU0,)'"92"8!.`5/4%TN*VVF7+
MDW6HYI@('*4%.1F4).V8D8F;50T:5+<31K85*1YC,$'`X3,^.$5_?>5V`/\`
MMT[Z\GX<C(YTAB&X+*93P')JE.9N[QC:WKM1O`E<F3(1=]1)E)U#+@'M<K5)
M40`%B\7_`*.OJ;_9&ZDJ_P!XV.1P;E#_`!#UAN!A5ZDM9M=Q6B7V"CS)XI.7
MBRWF1,8R;#MWUXV(;L\+[I*(+EP\QI:6ZUG@$%C(DN>/)8/JR^TQSRF*4R=@
MK3A=-(3>RDZ!%7TIAJ4OUH9OML>MSTIN(D"<9*&*5?BF1\FV-.SW!RVU[=2G
MLA0GT9':-A(QRSBX:Q+E2CYQQ=C[,>-)IM8J!D^GP%XJ$TU.0Z;^"L<<WDV"
MA@(8_2<)HK@FLF(\R2Q#$-P,40UR+54SU'4KHZD%+S2RDCB,"/3UP^V'VZIA
M%0R9MK2%#H(CT+7PCZQ`KYE]K\3V=MR8\_)\+8<+NO1QY^GEJI$Y/2'+QZGI
M\?1J[]W1`U;3$[G/]-45K5WW$[]9O_43$"7<^V&&SCV#.VSO0H\.+K(FU/;%
MB2-OAFB'4>S&"+E"1"$FJL)>*JQ*!;5&TB0`XE19O'Z@^'B%]TU?A0ZZK[4\
MKEIZEY13P6G'^^D$=($5>[VOXK3%+7-_GFFDS^KL\1/4"84>P#FZ][:\VXIW
M`8Q?FCK]A^]5R_5E8%#D1</J_()/%(IZ"8@*L7.LBJLG:8^RJU<*$$.`CIK7
M"@9N="Y;:@3;=0I/CR_LB1BAT-4Y15:*ALD*0H&?`>&._*+CG:MN,HF[G;GA
MS<IC1R#BFYCHL-<8U$3@HO$NWB(HSE=?&```)*M3S=RP<EX!RKMC!KD.Y6]Z
MUU[MOJ!)UI9!X[CT$2(Z8Z`HZI%;2HJ6^RM,^@Y$=1PB%3S%NZ.Z5C;MC+M_
MX!.K(;F>XS>XW"%9B8Y41DHS&3R5C6%YEURI&ZK5C/+R+6',J;E+\(Z>'X\$
M3<+?H"V,N5SE[KA_L*!!<)V%7S>F7:\40.IZM3=,FW,8U-0H"6])(!V;3)/1
M,Q!/YEK;%3]E>R?M-;5\?]/[-8B99DAG#Q)(J/VBM9H+'CVWVYR0"%-\=9K,
M_>/3\W$2]?E]!0U>N[>Y.7>\W2Y/SYG.0@;D@K"1T`2BK:OHTT%MHZ5!FE(6
M"=Y);)/69PK3M,_K6[7O[1V#/UH5;3-OOW)6?LSGL&*5:OO!KZXBZ;/](W\(
MW[XZX[^3TF.A3L\-D<==PW9H+NW:Z#5HT15<NG3E4B#=LV0(95=PNLH8J:2*
M"1!,8QA`I2@(CX:)*)DD3,^OJC"B`)J[`SZ(1MI^V8/,C[^=]^XF[3<U#;1=
MO>/;'M?VCRR#ETW9*Y+.UD"U&]-4DSB5ZP8RAE[7*M@`W7+)Q[8X\I1X.EZX
M_P#Y]8J*WL@?O1]?O:@'Z$P2GQ20D\%&%Y\)_%5?45#Q(I&P4-_6."=O2HX3
MQ`A,;+V*;U@G*>1,+Y.A'%=R'BRXSU%N$,Y(8AV<[7)!>/>],3`'59N3(`LW
M5#V5FZA#EX@8!TY:2J:N%*FIIE<S#J)IZ%`&<+BKIG*2H4P[@4D@](PW>64/
MC^5)[D),IX<L?;TRA.=6_8)9/;I@ES(NN+JQ8:D)$#3U0:BLISKNL9V"0*=%
M,O$WU5()E*`$:&'2+[T=._"UR+]2R^'?/*O@L"4_Q@)=(GMAH:)O'Q5.;:\?
MMFP2GB-NW?B.D[H<*'TZ4B1)(&Z+V)2!&Z-2?3+_``@_?#08]?)%.]W5"F)W
M,-_13E,4P;M\Z<2F`2F#C?9@0X@/`0X@/JUUSI3^6J']E;]D0@M0??%1^E7[
M:HG\\G:FH.\[=FL"9A2)M>A$SJ`'L%45RK73)D,/R&.5$XA\Q1TO>]W[MI/T
MR_9BU=W_`.L/?55YT18*RTK%P,7(SD])Q\)!P[)S)2\S,/6T;$Q4:R1.X>2$
ME(O54&;%DT;IF4555.4B9"B)A``TBD)4HA#8)4<@-IW80T%%(2>8R0!U"*F3
MOC[ML>;U.YCN"S/B61;S>,&1JEC"D6=J!OA+=%8TKC.N/+4Q,H1-16*G)Q)X
MJR4$/XUETCAX&``ZHT3::BSZ<8HZKU:C%:AM2I1)D>HB8A':FKV[A=W'FO6;
M!'*1N``\XGUQ*KY2_:SE.Y[W+9NT3@))AA;#6++M15[@Z:K(Q%AR'D`L2P9U
M"$>*$!.3?1,*DX?/P2$X-"]`J@E,LF!JQWJW6D:M";6#.M==!Y?HH29\W#F(
ME$[H>@J%5RJY0DRD''>2)>F?1CD1%BI\@_>_&&N??DAJC/PW15,^8J_;';QO
M]J8K_4KCO74^@/Y4I/J'VC".U7]^/_6_)$96^4^035[JSA4X")FVV',2B0@(
M@`&4FL?(FXAZ!]@XZA^]14M,`;?B4>942&A3_P!:Y=A:5Y)?+%EV'I'[X_BU
MS>.UUCS0X3F.J$J^V`(AYH_N@\/3]09]X?,/Z0,1:=&I?^VENZ6?85"]M'\W
MU)X.^V(Y7F&NPF%_1N^_S9/31^W[9)Y9]QN#:Q'<37MLB11U,9:Q]%-"<371
MJB4RTW&(D$95,IG2)?BRJE<_/N_UR*<IL=X6?AR9-.'YIG((62>R<@=F`.&(
M-4:8]_S7&A3]H)E2=A_"3YU)ZQM!1-J]ILM(LT!<Z9/S%4M]3F8^P5FRP+YS
M%3E>GHATF\C96+?MCI.6+]@[1*<ABB`E,7@/AQ#3O>9:J62R^`IM0D01,$',
M2/3E"S:==IW0XW,.)\-GHZ1%F7V(N]Y6.XM0&6!LZR<56-Z>.Z^525;&%M&Q
MN>:O%(@FMD6F-"@FBE8F:)2FGXE(.+=01=MR_"J&(WYOUQHMW3]0:RC!5:'%
M=;1.25'=N/4<<W)IS43=U9##YE7(S'TN(X[_`!@;!-)O#<)M=HNZERL(E20V
MWYP54$`$P@4F,[,)A`H>(CPU3;2)W6F&^H;]L1/7#]0?_0K]DQ"!Y4ANFCVB
MZH<@"!G&?,WKK<1X\5`EXAOQ#W0!-`H</NAJW]YA)U6[//W3?LQ$:5/_`$KI
M</F$,L?D?F_BU0(L<0Z=VC*N&<9-\'FR]W$MR>PE*97OP0AMO%9+8ELF&CTJ
MJI(?:LP8GR>JP0J1'"0M1_S(J@OU>/5Y0`EMTO2U53[[X:WL5\N6?O%<O)/F
ME+UTSYMN>0RB`OC[#/NR]5.TT^:7()\V6?JG+9TF(17.[?9:B4W/YDWN)-#*
M<W0,ZQDU*4!_)]D^V)`5@)Q#CP$./S:MXL]XV:>HS^/_`.K$!^]+:,[H^.E)
M^2/.+=O0V;1M?G)B.\S#W!)N5AHB2D&=?B<=QZ4E.N8]HNZ1@XU%?"4+'A+2
MJZ8((&<+I)@H<.<Y2\3!L-6:[J6$+T]1);4H`J*^SO)^T)'4/''AR[6\)*TW
M)Y1`)`"5B?FB'KMRY)V^Y3RMFC>7O=[J^ZW;#NCL$^6J4>WXKK5HM67K91SP
MC-K+RULN\7C2Z0[=DHR9,HM%C'BV$A6"W.4$C)EU<-0TUQIJ-FS6:UT]1;PF
M:DJ4D(2J<P`DJ!P,S.*_:JJB=J7*ZOK'6JJ>!`42H2E.8&Z6!V<(G!K^Y_9+
MU%B)^8Q[H[OI%(KP<T*P'`HE-R\1%WME>@H4?E+P`H_+QU27+;>DF1T_0">]
M29_Z@BPBOMAE_P!4JAT!7I289YV$14<UVSTNQP.Z',>\"JY$5>Y!J&:<YMHU
ME>9.M3Y6Y&$,+&.J%&,QB(H[)06Z3F.2=$,J?G$0Y>"VOBBNX.(<IFZ1UOU"
MVWBD'Z0/,KVHN=O1RTJ5!YQY!QYU9^*0,1=^8Y[=?_G@V,S&1J%!%D,^[4B3
M65*&#-N!Y6T49-B4^4:`F8A06<&D()B239I>T)G\8F0@<5C#JR]WVH562]H8
M=5_LJCU%3P`)P0H[!C@>!F<H@]5VH7"W*<0)U+(F)"<TYD#"9RGAM$ML5>A3
M`8I3E'B4P`8#!Z!*8.(#^$!UT^%`I$A,R\#"4*2D\JL"/1_3#['E,.X:6VT"
M^]NK)$Z92PXV+*Y6V]GD'(&4?X^E'R:F0Z)'BJISG-4K(^++-D2@(_"2;CE`
M$VW@A^]6P%A]N_,I]1SU'2/I#LK.[F'J_BC?#4T/=?>L*MKQ^T3-2>@YCQX^
M/=#H&D]#`B"#S*W['3<_\TKAP?\`YNT[5V[O/YLINAS_`$U17-6?<;OUD>VF
M,I^VICNI9%[1>SW%EWBT;#2+]LMQU3+7#/BE.C+5VU8Z;Q<TP6#E$H%<,7RA
M`$`XE\!#Q#4=J5YRGU755+"BEYNI*@1O!F#U1M6AM#UB8:<$VU,@$<")&*N+
M?WM%M>Q3=_G+:W:RNEAQE<7;>I3+E(Z?VIQS,E+-8]M*0F#@<)JJ/FQU>41`
MCH%4Q'F(.NFM/79F]6ABX-$36@<PGB%#!23T&8Z)';"7O%`Y;K@Y3N3P49&1
MQ&\=(D<,!ELAK_RD_<":1R.7>WODNP(,FB"4YGW!+N6>E20;MVR+8N8::W.X
M'E10;-T4+"@F`E(0H22H_+I5]ZU@4LM7^E3.<FG);YS;4/*D_BB+UH6ZCD7;
MGB)`%2?%ZPW9"?43&9O;"9O.ZKW;]T_=>M;962V];7GCW;%LI;/B&6BWKUBW
M>LY2]Q22Q%&O72KTFZDSF+[:;NSI`!N9L`A":F6G3.EJ73#)Y;A4?;5!Z1,(
M/"<@.".,2UJ2;M>7;LYC3LGE;\P\A*NE8W1C!YRK^:.P;_WFSS_ZGQSJ8[H/
MSU;T,_EQ$]X'88Z%^=$)G[3/ZUNU[^T=@S]:-6TW+[]R5G[,Y[!B@VK[P:^N
M(NFS_3-_"-^^.N.]G5Z3'0Q$\-G]$+]>8@WIVG;YM$B-L&#3/9+=+OSLJ6WW
M%<#`K#]HVM8L+AE%7Z?9)(*`Y15?M9=O!-5.4`*XE^H4W\080O6@+0S778W&
MNPM5"GWBR1A,3(&4L)$RSPEMBLZEKU4]*FD8(^,?]42(GRSD=NV?+/CPB1OM
ML;*:IV^]F6%ML-;(U<2E/KJ<KD>?;)%*-LRI9`++7VPJJ$\5D59I8S9IS"(I
ML&R"?H(&J_J"\.WV[NW!4_=J,D).QL8(2>@8G>23$I:Z%-OH44A$R!ZVV9.)
M\N`X`0I)YL_MW%KEMH/<:QI`B2(NQXC$NXQ./:@5)G;6344,99#?%2#V0GXE
ML:#>+"`%!9FQ`1$ZP\6MW5ZA*FW+!5*(6D%;1X?.1U'$#B=@BBZZM)"A<VAG
M@OI`$O&..8XPIKM+W,Y$V;[D,/[FL5NU$+EB*Y1UE;LP7.W;6.%`QF=HI\H)
M!]N'MM;<NHYR40$`3<"8/:*`@U;Q:Z>[VYVWO@>X>1*?T3*8(XSQ'$"*);JU
MRWUB*EHD%*AX'IR/"<7#.V?<-CG=A@+$^XW$TF64H&7:;%6^#/U"'=1QWJ8I
MRM?E"I^RA-UF817CWJ7\FZ;*%^37(UPH7[77.6^J$GVUE)'FEP(QA^4=8U7T
MR*IDS0L3XC>#T&/=D_IE_A!K3/9_&$;44^'=L_:A=P+^UKFO_?*1UUOI+^6J
M']F;]D0A=1??#_Z5?MJB23RXFV#,NZ3<#N.K&%MYF9-ETW6,,5Z=EKEAJ*@)
M:6N4<XNR$<A6YQ"P'31)%L'9P=$%(Q5!4#AQ`-5?O&N5';J2F<JZ1JK;6ZH!
M+A(Y,-D@<XG=&TKU2\[[IU34D'*>].Y2<3'8N_?@ONA[/++1,=[FM\^;]V>V
MO*S.57Q_;9:8L58JSZ<@U2#-4F^45C)N*\6UL&"Z#Q$5%G:+QJH*B7*9)5-/
MSH2MTU=FEOT%%3TMU:E-(`5ZOTTJ,C(Y$1ZU4S=Z!24U#ZW:18P,U2ZP2098
M<<<XC4[8.0.W]3]R%,BNXA@1?*F%K+/,(MU=6]^N=>9XN7<J)H,YZSTRLO&#
M6[TM%T8!DTCK$7;MA,J0JP)BB>RZGIKZ[;E*L#P;JDI)Y2E)*OJD]G@91"6)
MZUHJ@BY(YDDCUID2XX9]&6>V0BVGP_0\1XTQI3J?@FJT:FXECX*/7HT'C:,B
M(JEE@7[9)XP?P:$&FG&N6LFV6*N#DG.+GGZACG$PF'E.K?K*FJ4]6J<75<Q"
MRHGFF,/6GCGEE*'A3ML,M!NF"$L2!`2,)';/C'I7R#][\8:^._HC[#/PW15,
M^8J_;';QO]J8K_4KCO74^@/Y4I/J'VC".U7]^/\`UOR1&6?E.OVJ4A_9=R__
M`+P8[U#]ZO\`+`_:4>942&A?OO\`Y2_R8LM0](_?'\6N;QVNL>:'"<QU0E7V
MP/\`^H_N@_[`S[^L#$6G/J7_`+9V[I9]A4+ZT?S?4]#OMB'4^(@("`\!``_>
M#27D9S$,$0C1YASL("S-==_VR"D_YF/QUHW+8$JD<81;'$1<RV9,8P;%$>*)
MN)U[%$($#DX&?MB<OQ)`=?=_KL)Y+'>5Y2]TX3*>Y"R?$E1Z#LA<:KTQSE5R
MMR?7S6@;9[1PVD#+.$M,;Y'O6([W3\JXMMDS1\A4.>CK32[C6WJC&8@)R,6(
MX8OV+E(0X@!B\JB9N9)=(QDU"F(8Q1<U32LUE.NEJD!RE<!!GY87#+SU*^'&
MU*2\DSW$$18T['^]#0^YYVX=VU'OQX:D[Q,9;2\VJ9-HS8R;.,R!#ML86%H.
M5\=M3GYCPSYP8H2D>7F4B'BG+XMU$#FYVOFC:C36H:5]B:[0Y5-\JOHGG'JJ
MXC8K:,\8;M!?VKS9GDJDFN2RL$;QRG$#CM&PXY&._P#E5F_0[0M`4`XF^,S;
MG!R(<`#I\MG;M>0!XCS`(-^;C_RM:_>49ZK=GF&F_9$;VE?N@?I%><0R/^1^
M;^+5!BQQA+O.KN_.P1]#+L<LNTVO2#5S8AR*7=-4\BVAG(,E6T8%;1IWZ/WS
M,\>X3<D=?'&=`H4Y#)<@<2FU,VAVR-%9O*:I0PY?<J2F6<^;F!X2EQB-N#=S
M6$_NXL`XS]XDJW2E(CC/JB/)WC#O^G3YOM/V>WJI.'(DOB_<,F``80YA!0[E
M;E\`X_1\=3OQNAP)ANZ2W^\;B*+&J)=NA_L+S\<+>=X[+O<TRAE?#W:(RJ_V
M+V3)NXBUXUG)")VB4:]0\U$*RED50I4#D>PWH5%8F)=.$?K]RBT1ZQ6#!-95
M0$3@15@Z1IM-TU&]JI@5B&6$J2"^I)!PF2GED"?FB>$XJU]=O3SR+.^JG4ZX
M02&TD<`%$SW@X983B=+;SL1[W&U[#.-<#8ES'VI(N@XIK+&K5HDA@K,S^9<-
M6G.=Q)S4IU$59&<F'BRKEZY$I!7<K'/P#FX:I5??-'7*L<KJEBYEYU94J3K8
M$SL`V`;!/`19::W:@I6$T[2J/D0F0FE4^DF0F3G&0[#$_?W:.T%5,Q=I=1N"
MR7Q:*6%,_H'6;@<!6("B,PD<IQ)QY?'@!N'R:T5UFAU((0S=0YL)<:D/)'V%
M/J8'%=#_`.&OY8FY8)+HL623H&9':;5N5V$>D9%@#L$2?%"S2/Q.FU%?FZ8&
M]H"B''QXZIJRCG4I',>8X<V)ELGQE%C0"$B<IRQ`RG\D<@Z::Q#I*IIK)*D.
MDJBJ0JB2J2A1(HDJF<!*=-0@B!@$!`0'AK`)'K">&[.,F1P.451_?=[<Z_;M
MWR6V"JT>9'`N=?K7+^#'":8@VB(B6EE1M>.SF`QBE<T"P.101+QYC1B[,XAQ
M,.NH]"W\7^RH6Z9US("',<24B05T%,NN<)+5-I_==Q5R#[!PS3N`W#HR\6^(
MWMJ&Y7(6SW<9B#<OBUV=O<\07.-M+)KUCHM9^,2,9M8ZI*"0?XR(M5?<.6#D
MH@(=)P(@',`"%BN]MI[O;G;?4B;3B9<9[".(.(XB(>VUKMOK$531DI*AT=?#
M?PG%Q9MUSSC[=%@O%.X7%4D65H&7Z1!W>N..8IEVS:7:D4=1$@!/!&6@I`%6
M3Q(?%)T@H0?$-<BW"BJ+97NVZID'FE%)XR.8X$2(WP_:2I;K*9%2U^;6,!NW
M@\0<#$*WF@IY.$[/^:&IU.0]FR3A"O(!SB7J*'R'%2YR<`$.?_-X@YN`\0]G
MYM7#NV;+FK6)#!*'"?[!'G($06KSRV1>\K1Y%`^8&)#NU#^S-V&_V5<+_P"Y
M45J#U29ZCK0#_P"X7YXD;%]ST_Z(0NOYMS8>%TQ+BW?_`$6%ZECQ`Y9XCS:H
MQ;<5GF,[5)'5HEGD#(I\1)3[J\.P,H81$$9LG$0(D'"_]U5\4Q6N6-U0]TX"
MMN?TQ@H#I3CT@Q5=<6Q+U.BXH'KH/*KHV'JQ'21"+V'CY44R;3HC"+ZRL<JV
M^6)0*9]D'KN/L,C)Y#16I"L`R<,3$<=*Q,I]5BX(`\JC=P<IO9$=.RM^&32+
M75I2JB0)J"MZ3S`]0'DA:4?OA4)%,5!TGEPVSF,.)R'&+??MV[.ZML+V:X+V
MO5I%D9UCZG,C7F89)D*6T9,G2A,9!LIS@4IEB25F=K@W$W$R;--%/T$`-<F7
M^ZNWN[OW!1/*XOU`?FH2?4'0$^6'Y;*)%OH6Z4=H`%7%4L3XX5D\Y8X2"M;!
M6O$06-8,^.`#E'EZ1(O&R1AYO1QYU`\--#N?Q>K2,I->0KG%&U_BBGXA?G1"
M:VTS^M;M>_M'8-_6A5M-R^_<E9^S.>P8H-J^\&OKB+I1ZZ:,4';Y\Z;LF+)%
MP[>O7:R;=JT:-DSK.73EPL<B2#=NB0QSG,(%(4!$1``UQV!S>I(DG8-IG@,(
MZ%40!,Y#Y(0V0IO<=[S'<IRQW*MA<YA^D8PVB78V"=K%YW!M'<I37;6NQ\LU
MD;'1JVXJ=PBY2P/7,TXG'+I5`@,#RK,I#BLB7IO%+VGM):>:T[>PXNJJF^=Y
M+>8YC\X@@RD`D">/*3+&%N6[M>[HNYT!2&&5<J)D#++,*&WFRPYI1)X[PMYK
MY$Y2M]WVQ-X02\PJ)TJ`1`IN(AR"5QA(AQ'AX^'$/'5=^*[KR<::JZRHY="X
ME_<:O&3C9GQ3_P"7'B^>]D?F<-S^',@X#S?N(V'73%F3X!6MW"NN*Q!LC/(]
M19!TDLSD6&&D)"+DX]\V2<-73<Y%V[A(BA#`8H:W*&[]W%MK&ZZA9J6ZEM<P
MH!1V$$2Y\9SCX55!JJL853OK:4TK`@E/2,FP<]QA&'='MER[LZSUD7;?G.OE
MKN2\93!8N:;M5E'L3*-'39"0AK)7))1!M]:UNQ13E)VR<],@J)*>T4ARG(5V
MVJYT=XHFJ^B7SL.C#"4B/I#&1!PA85]#46ZI52U0`<3AAEU';L\<-9>4_P"X
M_P#83(EL[<^49\$JIE)Q+9'VZN)-T4B$/DAFS!S>\>LC+'*"2%VA6@RK-(!`
MH/V#D"@*CKQ5?>IIPO4Z-0,I`>;DAWEV@GU5=61Z8O>A[NI+AM3Y'*K%/2,Q
MUCS;S#])/IE^7Q#Q^]I%3]66X^0>&,,P><13W]VS]J%W`O[6N:_]\I'77&DO
MY:H?V9OV1"%U#C>'_P!*OVU0P=Y.1/\`^IK>@KT^(DP/CU/J\GT`4R$]/T^I
MP]D%.EQX<?:Y?FTON^#]2H\1,NJ]D"+7H#%]X#/W?I$.&]RC8I0NXKM$R?MJ
MNA6C&8FX\9_%MP71ZKB@96@45W%,M#8Y0%8K0'AA:2"9/%Q&NG"7I.`@I=/7
MNIL%V:N#4Y),EC8M!P4#QVIW&1B^7:VM7.A73*'VA!Y2=BI;.!R/"*AO*^+;
MY@_)M^PYE*O.ZKD7&-LFZ1=:\_3,1>,GX%ZJQ?)%$Y0Z[1<4P5;K%#D7;J$4
M*(E.`ZZSI*JGK:5%92R4PZE*DF>:2)D=4(>JIG:2H53NB3B#Y!XO#*'B/*U=
MV(UQKZ7;4SS915M%0C9";VL66:>F.XGJ:P3.^L&&C.'!Q,K(4Y`JC^$((B8\
M6*[<O`K1(HI+O-TJ6'?XAHD_8KD'@,@<@O\`&R5N,CM,,K1E\#S?[MJ5?:)F
M4$[1M3Z0.D`2E#IP>(#^[Y0^32=!!PF)D0PAO\,HJE_,5?MCMXW^U<5?J5QY
MKJ?0&.DZ0C+E/M&$;JO[\?\`K?DIC+?RG":A^Z?*'*0QB);7,NF4,`<0(!K%
MCHA1,/R`8X@`?/J'[U/Y9`V_$H\RHD-"_?7_`"E_DQ99!X"/'[H_X]<WY*!.
M1(\T.$^:7R0E7VP`'^]'=T$?]09]_6!B+3GU*9]V=N^LS["H7MH_F^I.P!W_
M`%!#J8_B#][29EA/9#"C0Q2G*8ARD.0Y1(<AP`Q#D,`E,0Q#`)3%,41`0'P$
M!UG+L]O?&"!D<H06\POV%5L4O+KOUV4TT38M?N'=EW"X/K$<83XX>N3]>7RC
MC^(9)#PH3Q8QW$U')%X1"IS.4"@S,H1L\]`:Z^(]W9;NL"I`DTXHX*V`*WD9
M).W">(Q6FJ=+A,[C0`^[,RI(^;QZ/-EE+E3]I-ZN..I]O;*!:IJH6-!A+QJ,
MY79!:.D/JJQ1+N#GHPZ[<P`XC9N%?KM72!^=%=!4Q#E$!TWGJ=BI;"'VPMK.
M1QQ!GS)XS$+QI]ZG65-E25R(/AX;HLQO*U-S-^T+C$1`@$<9ASNLB4HC[*1+
MXY;``AP]D0,W'\'#7-/>4/\`[8]O]VV?&@'TPZ-($JLC:IS]94^)F(8S_(_-
M_%JAQ9XVE@XB0`X>(B'C\_#7E1EC,S\,XR,<-DH5C[@?F3XK`DUE_!^UK9_N
M(RCG6@VJS8W)<\A8YF:UAV+LM??N(9]8&*,5];6N]1C60;F,T1(C&I/R`4X.
M"IF#F9MA[OA7ANJNM8PW1*`44H4DK(.(&,@..9V2BGW/4RZ<*:H6%E\3`*L@
M<I\LYSVB<IC&>]/':1NLW8X-[DE#[C&:\%9OW!7R/R'9;GDEM+T"XQ\M:4[G
M7)NI31X-VK6EHZ#D(*'G###(E2*S:_"HH%*FB7B5M76WVBJTXYIZAJ*>G:4V
M$I/,#V5)4)B>WED9;S%#HJFX4]X1=:ALN*YR2,)X@@X]<QAGXHL*MD?>@VU;
MZLHPV&,?XEW8XVR%+5B:LQF^9<$35/J;)&OM$GDFP<7=N_E*^5\*:@@W*8Y/
MB3%$">UP`4#>-)W&S,&K>=IG*0*`'NW$F<SA).<-6AO-+7*2TE*@X1D9;B<9
M$[CC*60VB)=]5B);#9E!HZ8(PYWJ;X<1;#\?5K(^8*SF2V1%LM04Z'B\*8LL
M.5K&,M]4OYKJ/XF`*`Q<8#...'Q+A1-'JB0G'F,`:E+1::F]5)IJ,M!825>N
ML($AGB<^B-2LK6J%`6\%%!W`'RD@"$3._P!]Q&2[I:^!Z3@+9ENEK=-P=+72
M?4R%DS#-KB+59G]RCX:-4AHFNPS";)$UYJE#$754<NS+.%^0`23*F)E'?H.P
MM:8]\]7UE.IUX)`2A:9)Y9XDDB<YRPZ9PMM45SMW2VS3,+"4<V)(QF1QX>7Q
MK@AMXW!\?Z`\W_\`"/(7_P`.Z8_[TMNVH9EM]=.7CBF_NVN'^4KR?+#(?9;[
MONZ[MGU&0V\9GV@[BLS[8W]@?VBMH5;&MU99&Q/.32I%I\M83FH)"$L54G'0
M"Z5C%UV1V[TZBR*_\:HF9;ZQTI:M1.BXT573-7`"2@I0Y5C9D<",I[8NFG;Q
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MEI=;'*#@9RZP29;`"2<L3*&G<ZX8HNXO#&4<$9+C4Y:@Y=HUDH-I9'(10_U7
M9(QQ'J/&O4`Q49&-46*Y;*^!D7"1#@("4!TLZ*L=H*MNOI_5>:6"#/<?,92Z
M"8MK[+=93JIW,6W$$>'$0CUV`NS=D3&W<]W!7K<54W85SM\VZ7IE$D96*<-X
M?(.8)\CI*DW2NJ.DB-Y.*@\>+C.$51,<&[R18^/.4>#HUWK&FJ=-L,T"A[VN
M2"L`XI0)$I/'FP.\3A>Z:T\Y379QZH3]FR3++$SD-N$I3D?P3MAW_/6:J9MQ
MPYD7.F1$;*YI&,*V[M5F0IU=DK=9U(QF=)-8L+6HA-62F'O,L'!)(HF$.(^@
M!TF*2F<K:I%(T4AU9D"H\J>LG*&+4/)8:4ZN?(D8R\/ZHKS_`##?<4HG<[G=
MM4+MHPAN4"MX0;9'?3]LR#A^R57ZZD[X:JH-8V#@TT9.0%M&-JT919RX%#G.
MN4A$Q`AC"^^[ZQO:<%2Y<GZ7WCW*``M*I!/-MGQA7ZLK?WM[INB;5R("L3+;
MRG>=T+[X?KF5,89=Q1DUSAG*<LVQQDV@W]S$H42VMEY1O3+9$61>-0<J0ATV
MZ[Y*-%(AS`)2&.`B`@&K_7O45;0O48?9276E(GS)PY@1//C%5HJ:JI:MNH4T
MHI0H&4Q#:G=L\P]?-TVWB:VV[)-N&YS&C#+,$6'S)E3(N.Y:"L[.JR;8OVAQ
MY0XJN#.BD:<*<[*0F%7*0BR%1-NCQ6ZQ%3I305+;ZX5]ZJJ9?NU30A"Q+F&2
MU3SEF!OSRB]7O4=34TII;>TXGG'K*41.1&0D3(#^B6,X]T[(_>LVU[5]FF$]
MF^=MO&Y7%MXQ[)R]?2M]0P;:;A2,@.KG=9*7;6B3<Q35"=A)Q=6<(@](X9JI
M%!`%"+B00(2/UOI*MN-W?O-'44SM.I(407$I4GE2$R$SCE,`;XW=.WAJGH4T
M=0T4.I4K(3G,DSSG/&6V<AMATKY`'[H`/S^(`/C\_`=*(R!E%V!F`=A$XQ]W
M0;EL>;1L-6/.F48V_P`O3:P\@V$@PQE19[(]Q6<6&6:PS`8ZIUM!S*O44W;L
MIEU"%Y4$@,<P@4!'6[;Z!^Z5::*F*`\HS'.H)3("9F3A&O5U+5(S[YZ?(",A
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MIXTS@QB&C>\5.D[9K]=ZG,V!LW(1[*4B?119%3B)=P4RJ3>2*U7:`?I',H!.
MJ9`W'N]K45BDVZHI'J$]E2G4I($\B)YC>)S\D-FDU&TNG2NI:=34!.('+*>V
M4S//?XS"&V\Z+S;N=W<[E]Q<!MIS_6X'-V;LC9,@X&6Q1>UI6)AK997\I%,I
M11K7U&HR23!9/K@D8R951,!3&*`&%Z65VAMEII[>[4L*=992@D+3(E(`)&,*
M^YT];6USM2EI02M:CC+:HGTRB6KR^N\%WVQ,]9LGMQ.V;=2[Q_FS'E;JQ+-0
ML&WJQR-3FJG//IEHK)5U:+CW+^(E49-5,ZK90Z[=1,@](Y3&$E2U_:V]243`
MMU12_$LN$D%:1S!<@<9R$@//$_I1]RTOK^+:66W$RF)8>4>$HL.-L6Y''V[7
M#%8SKB^-OL13+:YG&L:PR91IW'-Q06K\R]@G_P!9U*QMVTLP24>,#F0.<G*N
MB)5"")3`.D'<K>_:JLT524%](!]106,<O63A#1I*INK9]^V#R3EB)'J^48'9
M"DWFH^U>^N$?"=QO`U/>RMJB"PE!W,5FKP[N1E)Z!.=**H654XZ,;KN';ZOK
M&3AY50"B<62C-0?9;*&TUN['5**=Q5AKE@-$%314<!/%2,<L9J'&>\10]96,
MOH%SIA-V<E`;=@/F!ZC/.$L,>P>X[$][IV3L<TS,-0OV/[)$6^FVB'HMR;2<
M#8X)ZE(1<BT5)#@/,@Y1#F(/$BJ8F(<!(8P"XZEZU5E.NFJ7&5LK204E29$'
M?C%!IJ>XTKR7V4J2XDS!$HL']L7F=,!V;$%5/N@VY[MZ!G>/@V#*[1%!P!9;
MS3;18FC5)*1FZ5(,EF3MC'S+@AW!63]!`[/G%+JJ@0%3\_77N[K6*Q7[LJ*5
MVCYB4DN)2I(.PS.,LML_(&M1:F:=ITJK&U(J0,92D3+/,2]&.,)A=TW(E[WT
M;]]P^Z3'.WC/U;HF3K#7AJ<5:L6VU&QA"U6E5NFMI"9:L(M\S8/9?Z@%T+=-
M=<$"J@05#"`CIS:83266QT]OJ:BG+[:)*DH2G,F4YXRGG"YOJ7[A<W:IEM7N
MU*PG+<!OX1[)V5]RMU[:>]^&W"Y1VX;B+5C:4QU=,8W)A2<465Y:6+"TJPT@
MQFXIC+L8ID_^JY:!0,L@+E(ZB!S\@B8`*.CK.CI=264V^EJJ9+X<"P5+$B1,
M2PW@QL:<<=M5?\34-+4CE(D"!GU_U0Y1>_,S;/X"NOG]&VR;]LAV5./76BZ\
M.VN9J+)W)E1,9JPDYZ:E%$XU!5P!2*KI-W?2((F*100`HIRG[OKDZY*IJ:)M
M!.)]Z%8;P!E(99=4,2HU+2(3SM-NK6,A-(_*^6%0>WKW'<[[9NZCE?N%9UVK
M9JN,3N0<Y/99;KM%QM<2S54BLEV6)LS9Y1T9:(8L94U/=0#-L5JY50^+8D.`
M*)JB4=->_P!AMMRTLUI^BK&$KIPCD4M8,RA)20<9R5GPG%(M5QKJ:]+N-0RI
M33I5/+`*,_(?)A%@AL>[@F%=_M>O5APY4LZ4Y+'3^O1MDCLY8AL>)Y075E9R
M#Z/"%2G.HUGT448U0'"K-95-$PD`P\3EXH2\66KLCB&ZQ3*BL&1;6E8,I3.&
M6>$_1#/HZ]JO!4TE20!M`D.L$C9TRD92(C.;41@<LHW8V7+9L\;KLWC=!VT=
MH+-7;1TDFNV=-G"9D5VSE!4ITEVZZ1Q*<AP$IBB("`@.CFY2%"?.G(@R@5-:
M2%2,]ABO,\P7V&G.UZ3M.]S9U5%W.VZ:D%9?,N*(%HHX6P),R2ZIW5LKC)LF
M)OT/R;M0.LD4!^H'"G#_`*D<HMWYH+7*;@E-DO"@*X8(63(+PPG^&-^1&>(A
M5ZKTQ\.3<*!,Z<]H?1/R;CLR.$H8B\KL4?\`]0&'E/`2+93SV=(X"!BJ$+DV
M92$Y#%$0$H*)&#[X:7_>2H*U8\1E[MKV!%MT>A2;$V%"1YB?1#$OY'YOXM4.
M+/&A_D^A\OT_P>C1\T^`ZX(^O5H&48VQKHC,?)_HC]'Y/I_1](>G\7SZ(RG/
M;U1M#Z?Y#\/IT1B-/]'UD9P1ND^7Z'YGX]8/:ZNN"/O1!!H@@T00:((-$$;(
M?]#^#7G_`"]F75'I7:&?7G'T/H+_`,W^'T?)]'7K:(\CLGP'7&@>G^2^7T>G
MT?NX_-HW>'B@/9/1U1N!Z/D_!Z-!C"<MG5&NB,P:((T'T?)^'T:(P<MD;(_]
M!^'6?FCP$>CD,X^B>G^2]'Y'I_R:\[8Q&[K,$&B"#1!!H@@T01MG](?\W^?Z
M?P:RG/;U00%]/\GZ/R?3_DU\QGLC`RZXW->XS!H@@T00:((-$$&B"/@_R?0_
M/_%H':\)P1M?Z/K)S@@_T?6((Z7DS^C?(/\`,/\`F/;/Z3/Z-_\`L)]_2#_[
M#_\`>W_H/5U]Z7]9:_.=M/8[>?S/POH\8^51^K+[&1[?8R^=PW\(Q>[?7]5V
MF_U(O^VKE^SZ_JN_SED/YF_ZZ_[Y_P!9]74C??O%7ZYV$_K7Y[LCM?@_1_!E
?&M;?U0?F,S^9_-Y[.._C&;GR?)Z/P>C][4/&]'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
